Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells
2013 ◽
Vol 8
(3)
◽
pp. 259-269
◽
2015 ◽
Vol 11
(5)
◽
pp. 3259-3268
◽
2004 ◽
Vol 58
(5)
◽
pp. 1378-1387
◽
2014 ◽
Vol 9
(1)
◽
pp. 227-231
◽
2004 ◽
Vol 10
(7)
◽
pp. 2359-2367
◽
2007 ◽
Vol 67
(13)
◽
pp. 6253-6262
◽
2017 ◽
Vol 13
(6)
◽
pp. 2715-2722
◽